Efficacy of Preventive Pressurized Intraperitoneal Aerosol Chemotherapy in Patients With Locally Advanced Gastric Cancer: Protocol for a Prospective Controlled Trial
Wirksamkeit einer prophylaktischen pressurisierten intraperitonealen Aerosolchemotherapie bei Patient:innen mit lokal fortgeschrittenem Magenkarzinom: Protokoll einer prospektiven kontrollierten Studie
JMIR Research Protocols · 11.11.2025 · 14 · e78053
DOI: 10.2196/78053 ↗Auf einen Blick
Geplant ist zu prüfen, ob prophylaktisches PIPAC zusätzlich zur Standardtherapie die Rate peritonealer Metastasen bei lokal fortgeschrittenem Magenkarzinom senkt. Die Studie ist als kontrollierte, nicht randomisierte Studie angelegt.
Fragestellung
Reduziert die Zugabe von prophylaktischem PIPAC zur Standardtherapie die Inzidenz peritonealer Metastasen bei lokal fortgeschrittenem Magenkarzinom?
Methode
Einzentrische, nicht randomisierte kontrollierte Studie mit geplanter Einschlusszahl von 160 Patient:innen; 2 Gruppen: PIPAC + perioperative Chemotherapie + Gastrektomie mit D2-Lymphadenektomie vs. perioperative Chemotherapie + Gastrektomie mit D2-Lymphadenektomie.
Ergebnisse
Bis September 2025 wurden 102 Teilnehmende eingeschlossen. Rekrutierung geplant von Januar 2025 bis Dezember 2026; keine Interimsanalysen; primäre Ergebnisse für Q1 2027 geplant.
Schlussfolgerung der Autor:innen
Die Autor:innen vermuten, dass der neoadjuvante Einsatz von PIPAC die Inzidenz peritonealer Metastasen senken und langfristige Überlebensoutcomes verbessern könnte. Die Studie soll die Praktikabilität und Durchführbarkeit als prophylaktische Technik klären.
Kernaussagen
- Primärer Endpunkt: Inzidenz peritonealer Metastasen
- Geplante Stichprobe: 160 Patient:innen
- Bis September 2025 waren 102 Teilnehmende eingeschlossen
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Studienprotokoll in der Zeitschrift JMIR Research Protocols, online erschienen am 11.11.2025. Verfasst von Altay Kerimkulov und 12 weiteren Autor:innen. Beteiligte Einrichtung: National Research Oncology Center, Astana, null, Kazakhstan. Hauptthemen laut MEDLINE: Stomach Neoplasms, Peritoneal Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Gastric cancer is a serious health issue both globally and in Kazakhstan. Worldwide, gastric cancer ranks fifth in incidence, with the highest rates reported in East Asia, the Andes of South America, and Eastern Europe, while the lowest rates are reported in North America, Northern Europe, Africa, and Southeast Asia. Over 70% of the cases occur in resource-limited countries. In Kazakhstan, gastric cancer ranks third in morbidity and second in mortality, representing a serious clinical and social problem. Annually, 1600 deaths from malignant gastric neoplasms are registered. Peritoneal metastasis is considered one of the most severe complications of gastric cancer and has long been regarded as its terminal stage. The average life expectancy of patients with peritoneal metastasis is only 3-6 months, reflecting a high mortality rate and the limited efficacy of current treatments.
Objective
We hypothesize that the prophylactic use of pressurized intraperitoneal aerosol chemotherapy (PIPAC) may reduce the incidence of peritoneal metastasis. The aim of this study is to evaluate the incidence of peritoneal metastasis following prophylactic PIPAC in patients with gastric cancer. The primary goal of this research is to evaluate whether adding prophylactic PIPAC to standard treatment before neoadjuvant chemotherapy can reduce the incidence of peritoneal metastasis in patients with locally advanced gastric cancer.
Methods
This study is a single-center nonrandomized controlled trial with a planned enrollment of 160 patients. All participants will be included in one of the 2 groups: intervention group (PIPAC + perioperative chemotherapy + gastrectomy with D2 lymphadenectomy) or control group (perioperative chemotherapy + gastrectomy with D2 lymphadenectomy). The primary end point is the incidence of peritoneal metastasis, and the secondary end points are overall survival, recurrence-free survival, treatment-related adverse events, and personal satisfaction.
Results
As of September 2025, this study is funded and recruiting; 102 participants have already been enrolled. Recruitment is planned to be performed between January 2025 and December 2026. No interim analyses have been performed; primary results are planned for Q1 2027. The manuscript is expected to be published by Q4 2027.
Conclusions
Compared to standard chemotherapy, PIPAC has been reported to significantly improve survival rates in patients with peritoneal metastasis of gastric origin. We suggest that the neoadjuvant use of PIPAC may reduce the incidence of peritoneal metastasis and improve long-term survival outcomes. The results of our study will provide key information on the practicality and viability of PIPAC as a prophylactic technique for preventing the progression of gastric cancer. Trial Registration ClinicalTrials.gov NCT06784765; https://clinicaltrials.gov/study/NCT06784765 International Registered Report Identifier (IRRID) PRR1-10.2196/78053
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Research Oncology Center, Astana, null, Kazakhstan.
- Municipal hospital No. 1, Astana, null, Kazakhstan.
- Nazarbayev University, Astana, null, Kazakhstan.
ORCID-Profile: Altay Kerimkulov, Talgat Uskenbayev, Tomiris Sarina, Meiram Mamlin, Sanzhar Shalekenov, Gulfairus Yessenbayeva, Temirlan Kainazarov, Zhandos Burkitbayev, Baiduisen Ussipbekov, Dina Kovalchuk, Akhror Rakhmankulov, Aidana Rakhmankulova, Abduzhappar Gaipov
Zitieren
APA
Kerimkulov, A., Uskenbayev, T., Sarina, T., Mamlin, M., Shalekenov, S., Yessenbayeva, G., Kainazarov, T., Burkitbayev, Z., Ussipbekov, B., Kovalchuk, D., Rakhmankulov, A., Rakhmankulova, A., & Gaipov, A. (2025). Efficacy of Preventive Pressurized Intraperitoneal Aerosol Chemotherapy in Patients With Locally Advanced Gastric Cancer: Protocol for a Prospective Controlled Trial. JMIR Research Protocols, 14, e78053. https://doi.org/10.2196/78053
Vancouver
Kerimkulov A, Uskenbayev T, Sarina T, Mamlin M, Shalekenov S, Yessenbayeva G, et al. Efficacy of Preventive Pressurized Intraperitoneal Aerosol Chemotherapy in Patients With Locally Advanced Gastric Cancer: Protocol for a Prospective Controlled Trial. JMIR Research Protocols. 2025;14:e78053. doi:10.2196/78053
BibTeX
@article{Kerimkulov2025,
author = {Kerimkulov, Altay and Uskenbayev, Talgat and Sarina, Tomiris and Mamlin, Meiram and Shalekenov, Sanzhar and Yessenbayeva, Gulfairus and Kainazarov, Temirlan and Burkitbayev, Zhandos and Ussipbekov, Baiduisen and Kovalchuk, Dina and Rakhmankulov, Akhror and Rakhmankulova, Aidana and Gaipov, Abduzhappar},
title = {Efficacy of Preventive Pressurized Intraperitoneal Aerosol Chemotherapy in Patients With Locally Advanced Gastric Cancer: Protocol for a Prospective Controlled Trial},
journal = {JMIR Research Protocols},
year = {2025},
volume = {14},
pages = {e78053},
doi = {10.2196/78053}
}
EUVIMED